A New Standard of Care for Patients with Surgically Unresectable Stage III Non–small Cell Lung Cancer
Cancer(2019)
摘要
Overall survival data from the PACIFIC trial have reaffirmed earlier US Food and Drug Administration approval of durvalumab in patients with stage III non–small cell lung cancer. In the current commentary, the authors provide a brief historical perspective on stage III disease as well as a further analysis of the strengths and weaknesses of the trial.
更多查看译文
关键词
durvalumab,immune checkpoint inhibition,NSCLC,PACIFIC trial,stage III NSCLC
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要